Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 4, 2013, Pages 365-375

  Castellsague, Jordi ^a   Pisa, Federica ^b   Rosolen, Valentina ^c   Drigo, Daniela ^b,c   Riera Guardia, Nuria ^a   Giangreco, Manuela ^c   Clagnan, Elena ^d   Tosolini, Francesca ^d   Zanier, Loris ^d   Barbone, Fabio ^b,c   Perez Gutthann, Susana ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d Integrazione Socio Sanitaria e Politiche Sociali ^*  (Italy)

Author keywords

Case control studies; Cohort studies; Epidemiology; Friuli Venezia Giulia; Nonsteroidal anti inflammatory drugs; NSAIDs; Pharmacoepidemiology; Selective COX 2 inhibitors; Upper gastrointestinal complications

Indexed keywords

CELECOXIB; DICLOFENAC; ETORICOXIB; IBUPROFEN; KETOPROFEN; KETOROLAC; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB;

ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HOSPITAL DISCHARGE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; TREATMENT DURATION; UPPER GASTROINTESTINAL COMPLICATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; SULFONAMIDES;

EID: 84875812319     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3385     Document Type: Article

References (17)

1. Italian Medicines Agency, OsMed Working Group. The use of drugs in Italy. National report in 2008 [report in Italian], 2009. http://www.epicentro.iss.it/focus/farmaci/pdf/Osmed-2008.pdf [17 Jan 2012].
2. Helin-Salmivaara A, Saarelainen S, Grönroos JM, Vesalainen R, Klaukka T, Huupponen R. Risk of upper gastrointestinal events with the use of various NSAIDs: a case-control study in a general population. Scand J Gastroenterol 2007; 42: 923-932.
3. Laporte JR, Ibáñez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004; 27: 411-420.
4. García Rodríguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158: 33-39.
5. Menniti-Ippolito F, Maggini M, Raschetti R, Da Cas R, Traversa G, Walker AM. Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy. Eur J Clin Pharmacol 1998; 54: 393-397.
6. Pilotto A, Franceschi M, Leandro G, et al. The risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal anti-inflammatory drugs: the role of gastroprotective drugs. Aging Clin Exp Res 2003; 15: 494-499.
7. Cattaruzzi C, Troncon MG, Agostinis L, García Rodríguez LA. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database. J Clin Epidemiol 1999; 52: 499-502.
8. Pisa F, Drigo D, Riera-Guardia N, et al. Validation of primary and secondary ICD-9-CM codes for upper gastrointestinal complications in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf 2011; 20(Suppl. 1): S172.
9. Rothman KJ, Greenland S, Lash TL. Case-control studies. In: Modern epidemiology (3rd edn), Rothman KJ, Greenland S, Lash TL (eds). Lippincott Williams & Wilkins: Philadelphia; 2008; pp. 111-27.
10. Ray WA, Chung CP, Stein CM, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology 2007; 133: 790-798.
11. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol 1976; 103(2): 226-235.
12. Rothman KJ. Interactions between causes. In Modern epidemiology (2nd edn), Rothman KJ (ed.). Little, Brown and Company: Boston/Toronto, 1986; pp. 311-326.
13. Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther 2011; 33(5): 585-591.
14. Sadic J, Borgstrom A, Manjer J, Toth E, Lindell G. Bleeding peptic ulcer - time trends in incidence, treatment and mortality in Sweden. Aliment Pharmacol Ther 2009; 30(4): 392-398.
15. Hermansson M, Ekedahl A, Ranstam J, Zilling T. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002. BMC Gastroenterol 2009; 9: 25.
16. Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands. Aliment Pharmacol Ther 2006; 23(11): 1587-1593.
17. Italian Medicines Agency, OsMed Working Group. The use of drugs in Italy. National report in 2007 [report in Italian], 2008. http://www.agenziafarmaco.gov.it/allegati/rapporto_osmed_2007.pdf [17 Jan 2012].